Literature DB >> 6178839

MCF-specific murine monoclonal antibodies made against AKR-247 MCF virus recognize a unique determinant associated with the gp70-p-15(E) complex.

M W Cloyd, B Chesebro, J L Portis, M Weir.   

Abstract

Hybridomas obtained from (NFS X AKR)F mice immunized with syngeneic cells infected with AKR-247 MCF virus produced antibodies specific for only AKR-247 or closely related MCF viruses which hare a previously defined MCF antigen (MCFA-3). These monoclonal antibodies recognized a new type of viral antigenic determinant which appeared to be a conformational determinant associated with the env precursor polyprotein (pr80env) or its disulfide-linked gp70-p15(E) complex (gp80) but not with free gp70 or p15(E) or any other virion or virus-induced protein.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6178839      PMCID： PMC256853          DOI： 10.1128/JVI.41.3.1112-1117.1982

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  26 in total

1.  Continuous cultures of fused cells secreting antibody of predefined specificity.

Authors:  G Köhler; C Milstein
Journal:  Nature       Date:  1975-08-07       Impact factor: 49.962

2.  Qualitative and quantitative studies of AKR-type murine leukemia virus sequences in mouse DNA.

Authors:  S K Chattopadhyay; D R Lowy; N M Teich; A S Levine; W P Rowe
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1975

3.  An immunologic approach to the conformational equilibria of polypeptides.

Authors:  D H Sachs; A N Schechter; A Eastlake; C B Anfinsen
Journal:  Proc Natl Acad Sci U S A       Date:  1972-12       Impact factor: 11.205

4.  A film detection method for tritium-labelled proteins and nucleic acids in polyacrylamide gels.

Authors:  W M Bonner; R A Laskey
Journal:  Eur J Biochem       Date:  1974-07-01

5.  Presence of murine leukemia virus envelope proteins gp70 and p15(E) in a common polyprotein of infected cells.

Authors:  N G Famulari; D L Buchhagen; H D Klenk; E Fleissner
Journal:  J Virol       Date:  1976-11       Impact factor: 5.103

6.  Plaque assay techniques for murine leukemia viruses.

Authors:  W P Rowe; W E Pugh; J W Hartley
Journal:  Virology       Date:  1970-12       Impact factor: 3.616

7.  A new class of murine leukemia virus associated with development of spontaneous lymphomas.

Authors:  J W Hartley; N K Wolford; L J Old; W P Rowe
Journal:  Proc Natl Acad Sci U S A       Date:  1977-02       Impact factor: 11.205

8.  Tunicamycin, a new antibiotic. I. Isolation and characterization of tunicamycin.

Authors:  A Takatsuki; K Arima; G Tamura
Journal:  J Antibiot (Tokyo)       Date:  1971-04       Impact factor: 2.649

9.  Contained indirect viable-cell membrane immunofluorescence microassay for surface antigen analysis of cells infected with hazardous viruses.

Authors:  M W Cloyd; D D Bigner
Journal:  J Clin Microbiol       Date:  1977-01       Impact factor: 5.948

10.  A novel murine oncornavirus with dual eco- and xenotropic properties.

Authors:  P J Fischinger; S Nomura; D P Bolognesi
Journal:  Proc Natl Acad Sci U S A       Date:  1975-12       Impact factor: 11.205
View more
  13 in total

1.  A small region of the ecotropic murine leukemia virus (MuLV) gag gene profoundly influences the types of polytropic MuLVs generated in mice.

Authors:  M Lavignon; J Richardson; L H Evans
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  Friend and Moloney murine leukemia viruses specifically recombine with different endogenous retroviral sequences to generate mink cell focus-forming viruses.

Authors:  L H Evans; M W Cloyd
Journal:  Proc Natl Acad Sci U S A       Date:  1985-01       Impact factor: 11.205

3.  In vivo interactions of ecotropic and polytropic murine leukemia viruses in mixed retrovirus infections.

Authors:  Leonard H Evans; Marc Lavignon; Karin Peterson; Kim Hasenkrug; Shelly Robertson; Frank Malik; Kimmo Virtaneva
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

4.  Precise identification of endogenous proviruses of NFS/N mice participating in recombination with moloney ecotropic murine leukemia virus (MuLV) to generate polytropic MuLVs.

Authors:  A S M Alamgir; Nick Owens; Marc Lavignon; Frank Malik; Leonard H Evans
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

5.  Class II polytropic murine leukemia viruses (MuLVs) of AKR/J mice: possible role in the generation of class I oncogenic polytropic MuLVs.

Authors:  L H Evans; F G Malik
Journal:  J Virol       Date:  1987-06       Impact factor: 5.103

6.  Monoclonal antibodies against Aleutian disease virus distinguish virus strains and differentiate sites of virus replication from sites of viral antigen sequestration.

Authors:  R E Race; B Chesebro; M E Bloom; B Aasted; J Wolfinbarger
Journal:  J Virol       Date:  1986-01       Impact factor: 5.103

7.  Major histocompatibility complex class II-regulated immunity to murine leukemia virus protects against early T- but not late B-cell lymphomas.

Authors:  W L Vasmel; M Zijlstra; T Radaszkiewicz; C J Leupers; R E de Goede; C J Melief
Journal:  J Virol       Date:  1988-09       Impact factor: 5.103

8.  Analysis of two monoclonal antibodies reactive with envelope proteins of murine retroviruses: one pan specific antibody and one specific for Moloney leukemia virus.

Authors:  Leonard H Evans; Stefano Boi; Frank Malik; Kathy Wehrly; Karin E Peterson; Bruce Chesebro
Journal:  J Virol Methods       Date:  2014-02-17       Impact factor: 2.014

9.  A multistep process of leukemogenesis in Moloney murine leukemia virus-infected mice that is modulated by retroviral pseudotyping and interference.

Authors:  M Lavignon; L Evans
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

10.  Characterization of epitopes defining two major subclasses of polytropic murine leukemia viruses (MuLVs) which are differentially expressed in mice infected with different ecotropic MuLVs.

Authors:  M Lavignon; J L Walker; S M Perryman; F G Malik; A S Khan; T S Theodore; L H Evans
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.